Roots Analysis has done a detailed study on “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 290+ page report, which features 120+ figures and 135+ tables, please visit this link

Key Market Insights
 Over 90 firms are actively involved in providing in silico services for drug discovery of different types of biologics; of these, over 30 players claim to have the capabilities to offer services for all steps of discovery
 Majority of the companies offer structure-based drug design focused on early stage drug discovery of a range of large molecules, including antibodies, proteins and peptides
 Featuring the presence of small-mid sized firms, the in silico service provider landscape is well-distributed across various regions; these players have adopted various business models to cater to the evolving needs of the clients
 Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective in silico-based service portfolios and maintain a competitive edge in this industry
 The integration of novel computational techniques, such as artificial intelligence and cloud-based platforms, with in silico approaches is likely to revolutionize the overall drug discovery process
 Service providers are adopting various business strategies in order to continue providing significant cost saving advantages, along with expediting discovery timelines and improving product success
 Driven by the growing demand for effective therapeutics and increase in drug discovery efforts of various biologics across a wide range of therapeutic areas, the market is expected to witness sustained growth in future
 In the long-term, the projected opportunity is anticipated to be well distributed across various geographies, type of sponsors and sizes of in silico service providers

For more information, please visit https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Discovery and Development Timelines
3.3. Overview of In Silico Drug Discovery Tools
3.3.1. Historical Evolution of the In Silico Approach
3.3.2. Comparison of Traditional Drug Discovery Approaches and In Silico / Computer Aided Methods
3.3.3. In Silico / Computed Aided Approaches for Drug Design and Development

3.4. Applications of In Silico Tools in the Drug Discovery Process
3.4.1. Target Identification
3.4.1.1. Chemoinformatics-based Tools
3.4.1.2. Network-based Drug Discovery
3.4.1.3. Computational Platforms and Interaction Repositories

3.4.2. Target Validation

3.4.3. Hit Generation
3.4.3.1. High-Throughput Screening
3.4.3.2. Fragment Based Screening
3.4.3.3. Virtual Screening

3.4.4. Hit-to-Lead
3.4.4.1. Pharmacodynamics and Pharmacokinetics Modeling
3.4.4.2. Other Novel Approaches

3.4.5. Lead Optimization
3.4.5.1. Pharmacophore Modeling
3.4.5.2. Docking
3.4.5.3. Structure Activity Relationships (SAR) / Quantitative Structure Activity Relationship (QSAR)
3.4.5.4. Molecular Modeling

3.5. Advantages of using In Silico Tools for Drug Discovery Operations
3.6. Challenges Associated with Conducting In Silico Drug Discovery Operations In-house
3.7. Anticipated Rise in Outsourcing In Silico Drug Discovery Operations
3.8. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. In Silico Drug Discovery Services for Large Molecules: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Business Model
4.2.6. Analysis by Drug Discovery Steps
4.2.7. Analysis by Type of Large Molecule
4.2.7.1. Analysis by Type of Antibody
4.2.7.2. Analysis by Type of Protein
4.2.8. Analysis by Type of In Silico Approach Used
4.2.9. Analysis by Types of In Silico Services Offered
4.2.10. Analysis by Type of Clientele

4.3. In Silico Drug Discovery Services: List of Software / Technologies

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Logo Landscape: Analysis by Company Size and Location of Headquarters
5.3. Tree Map Representation: Analysis by Company Size and Drug Discovery Steps
5.4. World Map Representation: Regional Analysis of Outsourcing Activity
5.5. Grid Representation: Analysis by Type of Large Molecule, In Silico Approach Used and Type of Clientele

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Key In Silico Service Providers Based in North America
6.2.1. BioDuro
6.2.1.1. Company Overview
6.2.1.2. Funding and Investment Information
6.2.1.3. In Silico-based Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.1.5. Peer Group Benchmark Comparison

6.2.2. Creative Biostructure
6.2.2.1. Company Overview
6.2.2.2. Funding and Investment Information
6.2.2.3. In Silico-based Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.2.5. Peer Group Benchmark Comparison

6.2.3. GenScript
6.2.3.1. Company Overview
6.2.3.2. Funding and Investment Information
6.2.3.3. In Silico-based Service Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.3.5. Peer Group Benchmark Comparison

6.2.4. LakePharma
6.2.4.1. Company Overview
6.2.4.2. Funding and Investment Information
6.2.4.3. In Silico-based Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.2.4.5. Peer Group Benchmark Comparison

6.3. Leading Players Based in Europe
6.3.1. Abzena
6.3.1.1. Company Overview
6.3.1.2. Funding and Investment Information
6.3.1.3. In Silico-based Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.1.5. Peer Group Benchmark Comparison

6.3.2. BioNTech
6.3.2.1. Company Overview
6.3.2.2. Funding and Investment Information
6.3.2.3. Recent Developments and Future Outlook
6.3.2.4. Peer Group Benchmark Comparison

6.3.3. Sygnature Discovery
6.3.3.1. Company Overview
6.3.3.2. Funding and Investment Information
6.3.3.3. In Silico-based Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.3.5. Peer Group Benchmark Comparison

6.4. Leading Players Based in Asia-Pacific
6.4.1. ChemPartner
6.4.1.1. Company Overview
6.4.1.2. In Silico-based Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.1.4. Peer Group Benchmark Comparison

6.4.2. Sundia MediTech
6.4.2.1. Company Overview
6.4.2.2. Funding and Investment Information
6.4.2.3. In Silico-based Service Portfolio
6.4.2.4. Recent Development and Future Outlook
6.4.2.5. Peer Group Benchmark Comparison

6.4.3. Viva Biotech
6.4.3.1. Company Overview
6.4.3.2. Funding and Investment Information
6.4.3.3. In Silico-based Service Portfolio
6.4.3.4. Recent Development and Future Outlook
6.4.3.5. Peer Group Benchmark Comparison

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in North America
7.5. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Europe
7.6. Company Competitiveness Analysis: In Silico Drug Discovery Service Providers in Asia-Pacific and Rest of the World

8. KEY OPPORTUNITY AREAS
8.1. Chapter Overview
8.2. Key Assumptions and Parameters
8.3. Methodology
8.4. Antibodies
8.4.1. Developer Landscape
8.4.1.1. Number of Pipeline Molecules
8.4.1.2. Affiliated Market Size and Growth Rate
8.4.2. In Silico Service Providers for Antibodies: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

8.5. Peptides
8.5.1. Developer Landscape
8.5.1.1. Number of Pipeline Molecules
8.5.1.2. Affiliated Market Size and Growth Rate
8.5.2. In Silico Service Providers for Peptides: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

8.6. Proteins
8.6.1. Developer Landscape
8.6.1.1. Number of Pipeline Molecules
8.6.1.2. Affiliated Market Size and Growth Rate
8.6.2. In Silico Service Providers for Proteins: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

8.7. Other Advanced Therapies
8.7.1 Developer Landscape
8.7.1.1 Number of Pipeline Molecules
8.7.1.2 Affiliated Market Size and Growth Rate
8.7.2. In Silico Service Providers for Vectors: 3D Bubble Analysis Based on Number of Drug Discovery Steps, Strength of Service Portfolio and Company Size

9. EMERGING BUSINESS MODELS AND STRATEGIES
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. In Silico Service Providers: Analysis by Number of Large Molecules and Drug Discovery Steps Covered
9.3.1. Strategies for Short Term Success
9.3.2. Strategies for Long Term Success
9.4. Concluding Remarks

10. CASE STUDY: COMPARISON OF DRUG DISCOVERY PROCESSES OF SMALL MOLECULES AND LARGE MOLECULES
10.1. Chapter Overview
10.2. Small Molecule and Large Molecule Drugs / Therapies
10.2.1. Comparison of Key Specifications
10.2.2. Comparison of Manufacturing Processes
10.2.3. Comparison of Drug Discovery Processes
10.3. Approaches to Improve Discovery Process of Large Molecules

11. SURVEY INSIGHTS
11.1. Chapter Overview
11.2. Overview of Respondents
11.2.1. Designation of Respondents

11.3. Survey Insights
11.3.1. Drug Discovery Steps
11.3.2. Type of Molecules Handled
11.3.3. In Silico Drug Design Focused Service Portfolio
11.3.4. Likely Adoption of In Silico Tools for Large Molecules Drug Discovery
11.3.5. Current Market Opportunity
11.3.6. Likely Growth Rate
11.3.7. Cost Saving Potential of the In Silico Approach

12. COST SAVING ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions
12.3. Methodology
12.4. Overall Cost Saving Potential of In Silico Tools in Large Molecule Drug Discovery, 2020-2030
12.5. Concluding Remarks

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions

13.3. Overall In Silico Drug Discovery Services Market for Large Molecules, 2020-2030

13.3.1. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Drug Discovery Steps, 2020-2030
13.3.1.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Identification, 2020-2030
13.3.1.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Target Validation, 2020- 2030
13.3.1.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit Generation, 2020-2030
13.3.1.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Hit-to-Lead, 2020-2030
13.3.1.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Lead Optimization, 2020-2030

13.3.2. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Large Molecule, 2020-2030
13.3.2.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Antibodies, 2020-2030
13.3.2.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Proteins, 2020-2030
13.3.2.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Peptides, 2020-2030
13.3.2.4. In Silico Drug Discovery Services Market for Large Molecules: Share of Nucleic Acids, 2020- 2030
13.3.2.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Vectors, 2020-2030

13.3.3. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Company Size, 2020-2030
13.3.3.1. In Silico Drug Discovery Services Market for Large Molecules: Share of Small Companies, 2020-2030
13.3.3.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Mid-sized Companies, 2020-2030
13.3.3.3. In Silico Drug Discovery Services Market for Large Molecules: Share of Large Companies, 2020-2030

13.3.4. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Therapeutic Area, 2020-2030
13.3.4.1.In Silico Drug Discovery Services Market for Large Molecules: Share of Autoimmune Disorders, 2020-2030
13.3.4.2. In Silico Drug Discovery Services Market for Large Molecules: Share of Blood Disorders, 2020-2030
13.3.4.3.In Silico Drug Discovery Services Market for Large Molecules: Share of Cardiovascular Disorders, 2020-2030
13.3.4.4.In Silico Drug Discovery Services Market for Large Molecules: Share of Gastrointestinal and Digestive Disorders, 2020-2030
13.3.4.5. In Silico Drug Discovery Services Market for Large Molecules: Share of Hormonal Disorders, 2020-2030
13.3.4.6. In Silico Drug Discovery Services Market for Large Molecules: Share of Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS), 2020-2030
13.3.4.7. In Silico Drug Discovery Services Market for Large Molecules: Share of Infectious Diseases, 2020-2030
13.3.4.8. In Silico Drug Discovery Services Market for Large Molecules: Share of Metabolic Disorders, 2020-2030
13.3.4.9.In Silico Drug Discovery Services Market for Large Molecules: Share of Mental Disorders, 2020-2030
13.3.4.10.In Silico Drug Discovery Services Market for Large Molecules: Share of Musculoskeletal Disorders, 2020-2030
13.3.4.11.In Silico Drug Discovery Services Market for Large Molecules: Share of Neurological Disorders, 2020-2030
13.3.4.12.In Silico Drug Discovery Services Market for Large Molecules: Share of Oncological Disorders 2020-2030
13.3.4.13.In Silico Drug Discovery Services Market for Large Molecules: Share of Respiratory Disorders, 2020-2030
13.3.4.13.In Silico Drug Discovery Services Market for Large Molecules: Share of Skin Disorders, 2020-2030
13.3.4.14.In Silico Drug Discovery Services Market for Large Molecules: Share of Urogenital Disorders, 2020-2030
13.3.4.15.In Silico Drug Discovery Services Market for Large Molecules: Share of Others, 2020-2030

13.3.5. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Type of Sponsor, 2020-2030
13.3.5.1.In Silico Drug Discovery Services Market for Large Molecules: Share of Industry Players, 2020-2030
13.3.5.2.In Silico Drug Discovery Services Market for Large Molecules: Share of Non-Industry Players, 2020-2030

13.3.6. In Silico Drug Discovery Services Market for Large Molecules: Distribution by Key Geographical Regions, 2020-2030
13.3.6.1.In Silico Drug Discovery Services Market for Large Molecules: Share of North America, 2020-2030
13.3.6.1.1.In Silico Drug Discovery Services Market for Large Molecules: Share of US, 2020-2030
13.3.6.1.2.In Silico Drug Discovery Services Market for Large Molecules: Share of Canada, 2020-2030

13.3.6.2.In Silico Drug Discovery Services Market for Large Molecules: Share in Europe, 2020-2030
13.3.6.2.1.In Silico Drug Discovery Services Market for Large Molecules: Share in Germany, 2020-2030
13.3.6.2.2.In Silico Drug Discovery Services Market for Large Molecules: Share in France, 2020-2030
13.3.6.2.3.In Silico Drug Discovery Services Market for Large Molecules: Share in the UK, 2020-2030
13.3.6.2.4.In Silico Drug Discovery Services Market for Large Molecules: Share in Italy, 2020-2030
13.3.6.2.5.In Silico Drug Discovery Services Market for Large Molecules: Share in Spain, 2020-2030
13.3.6.2.6.In Silico Drug Discovery Services Market for Large Molecules: Share in Rest of Europe, 2020-2030
13.3.6.3.In Silico Drug Discovery Services Market for Large Molecules: Share in Asia-Pacific and Rest of the World, 2020-2030
13.3.6.3.1.In Silico Drug Discovery Services Market for Large Molecules: Share in China, 2020-2030
13.3.6.3.2.In Silico Drug Discovery Services Market for Large Molecules: Share in India, 2020-2030
13.3.6.3.3.In Silico Drug Discovery Services Market for Large Molecules: Share in Japan, 2020-2030

14. IN SILICO TOOLS AND UPCOMING TRENDS IN DRUG DISCOVERY
14.1. Chapter Overview
14.2. Owing to Potential Cost and Time-related Benefits, Outsourcing of Drug Discovery Operations is Expected to Increase in the Future
14.3. Technological Advancements are Likely to Revolutionize the Current Drug Discovery Processes
14.3.1. Integration of Artificial Intelligence in the Drug Discovery Process is Expected to Improve the Overall Efficiency and Productivity
14.3.2. Increased Adoption of Cloud Based Technology Platforms is Anticipated to Enhance the Scalability and Flexibility of the Drug Discovery Process
14.3.3. Rising Interest in Use of Force Fields for In Silico Drug Discovery
14.4. Concluding Remarks

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. ProSciens
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edelmiro Moman, Founder and Chief Executive Officer

15.3. Conifer Point Pharmaceuticals
15.3.1. Company Snapshot
15.3.2. Interview Transcript: John L Kulp, Chief Executive Officer and Chief Technical Officer

15.4. Evotec
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Mark Whittaker, Senior Vice President, Drug Discovery

15.5. Candidum
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Sven Benson, Founder

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

18. APPENDIX III: NON-COMPUTATIONAL METHODS FOR DRUG DISCOVERY

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]